Alcohol-related cirrhosis and liver cancer: a call for inclusion in non-communicable disease action plans [0.03%]
与酒精有关的肝硬化和肝癌：呼吁在非传染性疾病行动计划中予以纳入
Ajeet Singh Bhadoria,Archisman Mohapatra
Ajeet Singh Bhadoria
Yakira N David,Rachel B Issaka
Yakira N David
The under-recognised effects of serious endoscopic complications on practitioners [0.03%]
内镜严重并发症对操作者的影响未得到充分认识
Philip Berry,Sreelakshmi Kotha
Philip Berry
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
Alexa N Sasson
Alexa N Sasson
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial [0.03%]
克罗恩病排除饮食在中度至重度成人克罗恩病患者缓解期的诱导和维持作用（CDED-AD）：一项开放标签、试点随机试验
Henit Yanai,Arie Levine,Ayal Hirsch et al.
Henit Yanai et al.
Background: The Crohn's disease exclusion diet (CDED) with partial enteral nutrition is effective for induction of remission in children with mild-to-moderate Crohn's disease. We aimed to assess the CDED in adults with Cr...
Randomized Controlled Trial
The lancet. Gastroenterology & hepatology. 2022 Jan;7(1):49-59. DOI:10.1016/S2468-1253(21)00299-5 2022
Robin Baddeley,Enrique Rodriguez de Santiago,James Maurice et al.
Robin Baddeley et al.
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial [0.03%]
熊去氧胆酸预防减肥手术后出现症状的胆结石病（UPGRADE）：一项多中心、双盲、随机、安慰剂对照优越性试验
Sylke Haal,Maimoena S S Guman,Thomas C C Boerlage et al.
Sylke Haal et al.
Background: Rapid weight loss is a major risk factor for the formation of cholesterol gallstones. Consequently, patients with morbid obesity undergoing bariatric surgery frequently develop symptomatic gallstone disease. T...
Randomized Controlled Trial
The lancet. Gastroenterology & hepatology. 2021 Dec;6(12):993-1001. DOI:10.1016/S2468-1253(21)00301-0 2021
Richard Welbourn,Dimitri J Pournaras
Richard Welbourn
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial [0.03%]
使用Y90树脂微球放射栓塞联合尼伏单抗治疗晚期肝细胞癌（CA 209-678）：一项单中心、单臂、二期试验
David Tai,Kelvin Loke,Apoorva Gogna et al.
David Tai et al.
Background: Therapeutic synergism between radiotherapy and immune checkpoint blockade has been observed in preclinical models of hepatocellular carcinoma. We aimed to study the safety and efficacy of sequential radioembol...